查詢結果分析
相關文獻
- 利用SUMO融合技術於大腸桿菌中生產具生物活性之豬隻抗菌胜肽PR-39
- 魚類抗菌胜肽、基因轉殖技術的研究概況--中研院細生所臨海研究站陳志毅博士實驗室研究成果簡介
- 抗菌胜肽於動物腫瘤治療上之研發應用
- 抗菌胜肽之理論與應用
- Antimicrobial Peptides Characteristics and Their Applications as Feed Additives in Domestic Animals
- 具抗菌性乳製品素材之開發
- 穿越細胞膜--抗菌胜肽如何在細胞膜上打洞
- 利用大腸桿菌及嗜甲醇酵母菌生產具有抗菌活性之重組LsGRP1C
- 天然抗菌胜肽Nisin在食品中之應用
- 魚類抗菌胜肽於水產養殖之應用潛力
頁籤選單縮合
題 名 | 利用SUMO融合技術於大腸桿菌中生產具生物活性之豬隻抗菌胜肽PR-39=Production of Bioactive Porcine Antibacterial Peptide PR-39 in Escherichia coli Using SUMO Fusion Technology |
---|---|
作 者 | 陳正文; 宣詩玲; 林俊宏; 黃文正; 林慧傑; 王志鵬; | 書刊名 | 臺灣農業化學與食品科學 |
卷 期 | 54:1 2016.02[民105.02] |
頁 次 | 頁9-19 |
分類號 | 368.6 |
關鍵詞 | 抗菌胜肽; 小分子類泛素修飾蛋白質; 融合蛋白質; Antibacterial peptide; Small ubiquitin-like modifier; Fusion protein; |
語 文 | 中文(Chinese) |
中文摘要 | PR-39是一種分離自豬小腸、嗜中性白血球及脾臟之抗菌胜肽。此胜肽由39個胺基酸所組成,富含脯胺酸與精胺酸。過去之研究顯示,此胜肽除可抑制數種革蘭氏陰性菌與陽性菌之生長外,亦具有調控血管生成、促進傷口癒合及抑制癌細胞之侵入與轉移等生理活性。本研究之主要目的在於建立利用大腸桿菌生產重組PR-39之方法,以期獲得重組PR-39進行醫藥與飼料添加劑用途之可行性評估。研究中,依據大腸桿菌偏好之密碼子設計PR-39基因,並利用重疊延展聚合酶連鎖反應合成該基因。將密碼子最適化基因嵌入帶有小分子類泛素修飾蛋白質 (small ubiquitin-like modifier, SUMO)基因之表現載體中,建構融合表現載體,並轉形入大腸桿菌中進行融合蛋白質之表現。帶有組胺酸親和性標籤之重組SUMO-PR-39融合蛋白質可於大腸桿菌中以可溶型式進行表現,且可利用固定化金屬離子親和性層析法進行純化。純化之融合蛋白質以SUMO蛋白酶進行剪切後,再利用凝膠過濾層析法進行重組PR-39之純化。由1 L之培養菌體中可獲得55 μg之重組PR-39,純度高於95%以上。重組PR-39對大腸桿菌具有抑菌效果,最小抑制濃度為0.2 mg/mL。本研究已建立重組PR-39之生產技術。未來將進一步探討生產重組PR-39之最適條件。 |
英文摘要 | PR-39 is an antibacterial peptide that could be isolated from porcine small intestine, neutrophils, and spleen. The peptide is a proline-arginine-rich peptide with 39 amino acid residues. Previous studies showed that PR-39 exhibits antibacterial activity against several Gram-positive and Gram-negative bacteria. In addition to its antibacterial properties, PR-39 also exerted other biological activities such as regulation of angiogenesis, promotion of wound repair, and inhibition of cancer cell invasion and metastasis. The objective of this study is to establish a method for production of recombinant RP-39 (rPR-39) using Escherichia coli in order to obtain rPR-39 for further evaluating its potential applications as therapeutic agent and feed additive. The DNA sequence encoding the PR-39 was designed according to E. coli preferred codons and synthesized through overlapping extension polymerase chain reaction. The codon-optimized PR-39 gene was inserted into an expression vector which contains the small ubiquitin-like modifier (SUMO) gene for construction of fusion expression vector, and then this vector was transformed into E. coli. Recombinant His-tagged SUMO-PR-39 (rSUMO-PR-39) fusion protein was expressed in soluble form in E. coli and could be purified by immobilized metal ion affinity chromatography. After the rSUMO-PR39 fusion protein was cleaved by the SUMO protease, released rPR-39 was further purified by gel filtration. The typical yield of rPR-39 was 55 μg with purity above 95% from 1 L culture. The rPR-39 showed antibacterial activity against E. coli with a minimum inhibitory concentration of 0.2 mg/mL. This study has established a method for production of rPR-39. The optimal conditions for production of rPR-39 will be further determined. |
本系統中英文摘要資訊取自各篇刊載內容。